JERAYGO

This brand name is authorized in Austria, Estonia, Lithuania

Active ingredients

The drug JERAYGO contains one active pharmaceutical ingredient (API):

1 Aprocitentan UNII MZI81HV01P - APROCITENTAN

Endothelin (ET)-1, via its receptors (ETA and ETB), mediates a variety of effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation and is upregulated in hypertension. Aprocitentan is a dual ERA that inhibits the binding of ET-1 to ETA and ETB receptors and hence the effects mediated by these receptors. Read about Aprocitentan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JERAYGO Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02KN01		C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KN Other antihypertensives
Discover more medicines within C02KN01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3083475, 3083486
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1100108, 1100109, 1100110, 1100111